In an adult with a large coronary thrombus scheduled for staged percutaneous coronary intervention, how long should a glycoprotein IIb/IIIa inhibitor be infused?

GP2B3A Infusion Duration for Large Coronary Thrombus Prior to Staged PCI

For large coronary thrombus requiring staged PCI, glycoprotein IIb/IIIa inhibitors should be infused for 12-18 hours prior to the intervention, based on current guideline-recommended dosing regimens.

Recommended Infusion Protocols

The 2021 ACC/AHA/SCAI guidelines provide specific dosing for GP IIb/IIIa inhibitors 1:

• Abciximab: Bolus 0.25 mg/kg followed by 0.125 mcg/kg/min infusion (maximum 10 mcg/min) for 12 hours
• Eptifibatide: Double bolus 180 mcg/kg (10 minutes apart) followed by 2.0 mcg/kg/min infusion for up to 18 hours
• Tirofiban: Bolus 25 mcg/kg over 3 minutes followed by 0.15 mcg/kg/min infusion for up to 18 hours

Evidence Supporting Pre-PCI Infusion Strategy

The CAPTURE trial specifically demonstrated efficacy of an 18-24 hour infusion of abciximab prior to PCI in patients with unstable angina refractory to conventional therapy 2. This supports the concept of upstream GP IIb/IIIa inhibitor use before staged intervention in high thrombus burden situations.

Clinical Application Algorithm

For staged PCI with large thrombus burden:

1. Initiate GP IIb/IIIa inhibitor immediately upon identification of large thrombus
2. Continue infusion for 12-18 hours before planned PCI (depending on agent selected)
3. Maintain infusion during PCI and continue post-procedure as per standard protocols
4. Monitor platelet count at baseline and during infusion (risk of thrombocytopenia, particularly with eptifibatide) 2

Important Caveats

Bleeding risk considerations: GP IIb/IIIa inhibitors significantly increase bleeding risk. In one registry analysis, GPI use was associated with a 3-fold higher rate of bleeding events (2.9% vs 0.9%, P=0.015) and was the only independent predictor of 30-day bleeding (HR 4.76) 3. This must be weighed against potential thrombotic benefit.

Efficacy in modern era: With contemporary potent P2Y12 inhibitors (ticagrelor/prasugrel), the added benefit of GP IIb/IIIa inhibitors is less clear. One study found no significant reduction in 1-year major adverse cardiovascular events with GPI use in thrombus-containing lesions (HR 1.33, P=0.253) 3. However, this was not specifically in the staged PCI population.

Alternative approach: For immediate thrombus reduction, intracoronary infusion via perfusion catheter (mean infusion time 55±55 seconds) achieved 52% thrombus reduction and TIMI flow improvement in 69.6% of patients 4. This represents a different strategy than prolonged systemic infusion.

Practical Recommendation

The 12-18 hour pre-treatment window allows for:

• Maximal platelet inhibition before mechanical intervention
• Potential thrombus dissolution or stabilization
• Coordination of staged procedure timing
• Assessment of bleeding risk before proceeding

Abciximab or tirofiban are preferred over eptifibatide for this indication given the specific evidence from CAPTURE trial 2, though abciximab availability may be limited in the United States 1.